SCHEMBL5869971

SCHEMBL5869971

ClCCC(Oc1cccc2cc[nH]c12)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 13/20 0.44
SLC6A4 P31645 10/20 0.44
BCHE P06276 3/20 0.39
AHR P35869 1/20 0.38
CYP1A2 P05177 4/20 0.38
CYP3A4 P08684 4/20 0.38
CYP2D6 P10635 4/20 0.38
TSHR P16473 3/20 0.38
SLC6A3 Q01959 3/20 0.38
KMT2A Q03164 2/20 0.38
CHRM1 P11229 2/20 0.38
ADRA2B P18089 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HRH1 P35367 2/20 0.38
OPRM1 P35372 2/20 0.38
DRD3 P35462 2/20 0.38
OPRK1 P41145 2/20 0.38
HTR2B P41595 2/20 0.38
KCNH2 Q12809 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5870139 1.00 SLC6A2 (0.44) SLC6A2SLC6A4BCHEAHRCYP1A2
SCHEMBL5869968 1.00 SLC6A2 (0.44) SLC6A2SLC6A4BCHEAHRCYP1A2
SCHEMBL5870124 0.78 HTR1A (0.46) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL7881249 0.78 HTR1A (0.46) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL5870129 0.78 HTR1A (0.46) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL5334267 0.78 BCHE (0.44) SLC6A2SLC6A4BCHEAHRSLC6A3
SCHEMBL9983096 0.75 SLC6A2 (0.44) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL9293469 0.75 SLC6A2 (0.44) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL9293360 0.73 SLC6A9 (0.53) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL5869174 0.73 SLC6A2 (0.44) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037932-B2 Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY (US) 2006-05-02 US disclosed
EP-1397129-B1 HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS LILLY CO ELI (US) 2005-11-16 EP disclosed
US-20040176435-A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176435-A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors ADRA2C, ADRB1, TPH1 SLC6A2 5/4885SLC6A4 7/4885BCHE 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.